3 completed, 3 terminated, 1 active not recruiting. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 3, Completed 2, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Alpine Immune Sciences, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| A Study of ALPN-303 in Adult Healthy Volunteers ALPN-303, Placebo - Healthy Volunteers | Phase 1 | Completed | Alpine Immune Sciences, Inc. | 72 | 2021-11-15 | 2023-05-09 |
| ALPN-202 With PD-1 Inhibition in Advanced Malignancies ALPN-202, pembrolizumab KEYTRUDA® - Advanced Solid Tumor, Lymphoma | Phase 1 | Terminated | Alpine Immune Sciences, Inc. | 29 | 2021-06-22 | 2024-03-01 |
| An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies ALPN-202 - Advanced Solid Tumor, Lymphoma | Phase 1 | Terminated | Alpine Immune Sciences, Inc. | 62 | 2020-06-02 | 2023-06-05 |
| ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD ALPN-101 - Graft Vs Host Disease | Phase 1 | Terminated | Alpine Immune Sciences, Inc. | 1 | 2020-05-11 | 2023-08-28 |
| Cell Surface Marker Expression in Autoimmune Diseases Systemic Lupus Erythematosus, Sjogren's Syndrome | Completed | Alpine Immune Sciences, Inc. | 14 | 2019-06-12 | 2020-08-27 | |
| Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety ALPN-101, Placebo - Healthy Volunteers | Phase 1 | Completed | Alpine Immune Sciences, Inc. | 96 | 2019-01-29 | 2019-12-05 |
Lymphoma (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Graft vs Host Disease (1) · Granulomatosis with Polyangiitis (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Microscopic Polyangiitis (1) · Multiple Sclerosis (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
ALPN-101 (2) · pembrolizumab (1)
Australia (4) · United States (4) · Canada (1) · Puerto Rico (1) · South Korea (1)
Allison Naumovski, Ph.D. (2) · Jan Hillson, MD (2) · Stanford Peng, MD PhD (1)